Transition Therapeutics to Hold Conference Call on Third Quarter Fiscal 2013 Financial Results on Tuesday, May 7th, at 4:30 P.M.

 Transition Therapeutics to Hold Conference Call on Third Quarter Fiscal 2013
           Financial Results on Tuesday, May 7th, at 4:30 P.M. EST

PR Newswire

TORONTO, May 6, 2013

TORONTO, May 6, 2013 /PRNewswire/ - Transition Therapeutics Inc. ("Transition"
or the "Company")  (NASDAQ: TTHI,  TSX: TTH) will  hold a  conference call  on 
Tuesday, May 7th, 2013 at 4:30 P.M.  EST to discuss Third Quarter Fiscal  2013 
financial results. Dr. Tony Cruz, Chairman and Chief Executive Officer of the
Company, will host the  call. Transition will  announce its financial  results 
for this period in a press release to  be issued prior to the call. In  order 
to participate  in  the conference  call,  please call  1-800-406-9725  (North 
America), 1-303-223-2682  (International). A  replay of  the conference  call 
will be available on  Transition's website  for 
seven days following the call.

About Transition

Transition is a biopharmaceutical  company, developing novel therapeutics  for 
disease indications with large markets. The Company's lead CNS drug  candidate 
is ELND005 for  the treatment  of Alzheimer's disease  and bipolar  disorder. 
Transition's lead metabolic drug candidate is TT-401 for the treatment of type
2 diabetes and accompanying  obesity. The Company's shares  are listed on  the 
NASDAQ under the symbol "TTHI" and the Toronto Stock Exchange under the symbol
"TTH".  For   additional  information   about   the  Company,   please   visit

Notice to  Readers: Information  contained  in our  press releases  should  be 
considered accurate only as of the date  of the release and may be  superseded 
by more recent information we have disclosed in later press releases,  filings 
with the OSC, SEC or otherwise. Except for historical information, this  press 
release may  contain  forward-looking statements,  relating  to  expectations, 
plans or prospects  for Transition, including  conducting clinical trials  and 
potential efficacy  of  its products.  These  statements are  based  upon  the 
current expectations and beliefs of Transition's management and are subject to
certain risks  and uncertainties  that could  cause actual  results to  differ 
materially from those described in the forward-looking statements. These risks
and uncertainties include  factors beyond  Transition's control  and the  risk 
factors and other  cautionary statements discussed  in Transition's  quarterly 
and annual filings with the Canadian commissions.

SOURCE Transition Therapeutics Inc.


For further information on Transition, or
Dr. Tony Cruz
Chief Executive Officer
Transition Therapeutics Inc.
Phone: 416-260-7770, x.223
Press spacebar to pause and continue. Press esc to stop.